Anila Lingamneni
Net Worth
Last updated:
What is Anila Lingamneni net worth?
The estimated net worth of Ms. Anila Lingamneni is at least $4,754,342 as of 6 May 2024. She owns shares worth $657,045 as insider, has earned $715,977 from insider trading and has received compensation worth at least $3,381,320 in Haemonetics Corporation.
What is the salary of Anila Lingamneni?
Ms. Anila Lingamneni salary is $845,330 per year as Executive Vice President & Chief Technology Officer in Haemonetics Corporation.
How old is Anila Lingamneni?
Ms. Anila Lingamneni is 58 years old, born in 1967.
What stocks does Anila Lingamneni currently own?
As insider, Ms. Anila Lingamneni owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Haemonetics Corporation (HAE) | Executive Vice President & Chief Technology Officer | 12,295 | $53.44 | $657,045 |
What does Haemonetics Corporation do?
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Anila Lingamneni insider trading
Haemonetics Corporation
Ms. Anila Lingamneni has made 7 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently she sold 2,305 units of HAE stock worth $218,975 on 6 May 2024.
The largest trade she's ever made was exercising 2,305 units of HAE stock on 11 Sep 2023. As of 6 May 2024 she still owns at least 12,295 units of HAE stock.
Haemonetics key executives
Haemonetics Corporation executives and other stock owners filed with the SEC:
- Mr. Christopher A. Simon (61) Chief Executive Officer, Pres & Director
- Mr. Josep Lluis Llorens (63) Senior Vice President of Global Manufacturing & Supply Chain
- Mr. William P. Burke (57) Chief Financial Officer & Executive Vice President
- Ms. Anila Lingamneni (58) Executive Vice President & Chief Technology Officer
- Ms. Michelle L. Basil (53) Executive Vice President, Gen. Counsel & Sec.